SRR2016958
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- ALLOGRAFT_REJECTION+0.330
- INTERFERON_GAMMA_RESPONSE+0.320
- INFLAMMATORY_RESPONSE+0.310
- INTERFERON_ALPHA_RESPONSE+0.290
- IL6_JAK_STAT3_SIGNALING+0.280
- IL2_STAT5_SIGNALING+0.240
- PANCREAS_BETA_CELLS+0.240
- TNFA_SIGNALING_VIA_NFKB+0.230
Top 10 suppressed
- PROTEIN_SECRETION-0.340
- ANDROGEN_RESPONSE-0.290
- MYC_TARGETS_V1-0.280
- MTORC1_SIGNALING-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.240
- GLYCOLYSIS-0.230
- NOTCH_SIGNALING-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- ESTROGEN_RESPONSE_EARLY-0.200
- PEROXISOME-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.787 |
| 2 | MNG1140 | — | — | 0.769 |
| 3 | TCGA-E2-A1LH-01A-11R-A14D-07 | — | E | 0.760 |
| 4 | 0ec02d90-7ccb-476e-a8bb-9a9c8f158dee | — | — | 0.759 |
| 5 | TCGA-FD-A5BT-01A-11R-A26T-07 | — | — | 0.758 |
| 6 | SRR8518127 | — | D | 0.757 |
| 7 | SRR25617829 | — | D | 0.749 |
| 8 | R83 | — | — | 0.746 |
| 9 | TCGA-BH-A0BF-01A-21R-A12P-07 | — | D | 0.746 |
| 10 | f426318a-9c1a-4476-a087-2b3a84096f5c | — | — | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |